144 related articles for article (PubMed ID: 2427189)
1. Proliferative potential of human meningiomas of the brain. A cell kinetics study with bromodeoxyuridine.
Hoshino T; Nagashima T; Murovic JA; Wilson CB; Davis RL
Cancer; 1986 Oct; 58(7):1466-72. PubMed ID: 2427189
[TBL] [Abstract][Full Text] [Related]
2. Bromodeoxyuridine labeling study of intracranial meningiomas: proliferative potential and recurrence.
Lee KS; Hoshino T; Rodriguez LA; Bederson J; Davis RL; Wilson CB
Acta Neuropathol; 1990; 80(3):311-7. PubMed ID: 2399811
[TBL] [Abstract][Full Text] [Related]
3. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.
Shibuya M; Hoshino T; Ito S; Wacker MR; Prados MD; Davis RL; Wilson CB
Neurosurgery; 1992 Apr; 30(4):494-7; discussion 497-8. PubMed ID: 1584346
[TBL] [Abstract][Full Text] [Related]
4. Proliferative activity of meningiomas as evaluated by bromodeoxyuridine uptake examination.
Fukui M; Iwaki T; Sawa H; Inoue T; Takeshita I; Kitamura K
Acta Neurochir (Wien); 1986; 81(3-4):135-41. PubMed ID: 3529838
[TBL] [Abstract][Full Text] [Related]
5. Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling.
Cho KG; Hoshino T; Nagashima T; Murovic JA; Wilson CB
J Neurosurg; 1986 Dec; 65(6):790-4. PubMed ID: 3772477
[TBL] [Abstract][Full Text] [Related]
6. [A cell kinetic study of human central nervous system tumors with 5-bromodeoxyuridine (BrdU)].
Nagashima T; Hoshino T
No To Shinkei; 1985 Dec; 37(12):1195-201. PubMed ID: 3912000
[TBL] [Abstract][Full Text] [Related]
7. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
8. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time.
Kakinuma K; Tanaka R; Onda K; Takahashi H
Acta Neurochir (Wien); 1998; 140(1):26-31; discussion 31-2. PubMed ID: 9522904
[TBL] [Abstract][Full Text] [Related]
9. The proliferative potential of human ependymomas measured by in situ bromodeoxyuridine labeling.
Nagashima T; Hoshino T; Cho KG; Edwards MS; Hudgins RJ; Davis RL
Cancer; 1988 Jun; 61(12):2433-8. PubMed ID: 3284636
[TBL] [Abstract][Full Text] [Related]
10. [Proliferation kinetics of human brain tumors by in situ double labeling with bromodeoxyuridine and iododeoxyuridine].
Maeda T; Hoshino T
No To Shinkei; 1992 Sep; 44(9):821-5. PubMed ID: 1476811
[TBL] [Abstract][Full Text] [Related]
11. In situ analysis of cell kinetics in human brain tumors. A comparative immunocytochemical study of S phase cells by a new in vitro bromodeoxyuridine-labeling technique, and of proliferating pool cells by monoclonal antibody Ki-67.
Morimura T; Kitz K; Budka H
Acta Neuropathol; 1989; 77(3):276-82. PubMed ID: 2922990
[TBL] [Abstract][Full Text] [Related]
12. S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine.
Hoshino T; Nagashima T; Cho KG; Murovic JA; Hodes JE; Wilson CB; Edwards MS; Pitts LH
Int J Cancer; 1986 Sep; 38(3):369-74. PubMed ID: 3527993
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical demonstration with anti-bromodeoxyuridine monoclonal antibody in experimental meningeal carcinomatosis model.
Huang TY; Hwang SL; Howng SL
Kaohsiung J Med Sci; 1997 Mar; 13(3):136-40. PubMed ID: 9109299
[TBL] [Abstract][Full Text] [Related]
14. Cell kinetics of the malignant evolution of meningothelial meningioma.
Iwaki T; Takeshita I; Fukui M; Kitamura K
Acta Neuropathol; 1987; 74(3):243-7. PubMed ID: 3673517
[TBL] [Abstract][Full Text] [Related]
15. S phase fraction of human bladder tumor measured in situ with bromodeoxyuridine labeling.
Nemoto R; Uchida K; Hattori K; Shimazui T; Nishijima Y; Saito S; Koiso K; Harada M
J Urol; 1988 Feb; 139(2):286-9. PubMed ID: 3276925
[TBL] [Abstract][Full Text] [Related]
16. Proliferating cell nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumours in paraffin embedded sections.
Sasaki A; Naganuma H; Kimura R; Isoe S; Nakano S; Nukui H; Suzuki K; Kawaoi A
Acta Neurochir (Wien); 1992; 117(3-4):178-81. PubMed ID: 1357920
[TBL] [Abstract][Full Text] [Related]
17. In-vivo proliferative potential of primary human brain tumors; its correlation with histological classification and morphological features: II. Nonglial tumors.
Dinda AK; Kharbanda K; Sarkar C; Roy S; Mathur M; Banerji AK
Pathology; 1993 Jan; 25(1):10-4. PubMed ID: 8391143
[TBL] [Abstract][Full Text] [Related]
18. Radiation-induced meningiomas and their proliferative activity. Cytokinetic study using bromodeoxyuridine.
Tashima T; Fukui M; Nishio S; Fujii K; Iwaki T
Acta Neurochir (Wien); 1990; 102(1-2):69-72. PubMed ID: 2305653
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma.
Nemoto R; Uchida K; Shimazui T; Hattori K; Koiso K; Harada M
J Urol; 1989 Feb; 141(2):337-40. PubMed ID: 2643726
[TBL] [Abstract][Full Text] [Related]
20. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma.
Cobb MA; Husain M; Andersen BJ; al-Mefty O
J Neurosurg; 1996 Jan; 84(1):85-90. PubMed ID: 8613841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
